Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials

Movement Disorders

Volumn 33, Issue 5, 2018, Pages 697-700

  Cedarbaum, Jesse M ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LEVODOPA; SYNUCLEIN; ANTIPARKINSON AGENT;

ARTICLE; COAL MINING; DISEASE ASSOCIATION; DISEASE COURSE; ELEPHANT; FUNCTIONAL DISEASE; HUMAN; MULTIMODAL IMAGING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROOF OF CONCEPT; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; ANIMAL; CLINICAL TRIAL (TOPIC);

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; ELEPHANTS; HUMANS; PARKINSON DISEASE;

EID: 85046350638     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27398     Document Type: Article

References (25)

1. Parkinson J. An Essay on the Shaking Palsy. London: Whittingham and Rowland Sherwood, Neely and Jones; 1817.
2. Goetz CG. Charcot on Parkinson's Disease. Mov Disord 1986;1:27-32.
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
4. Polymeropoulos MH, Lavedan C, Leroy E., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
5. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
6. Lang AE, Espay AJ. Which therapeutic developments are more likely to modify progression in Parkinson's disease? Mov Disord 2018 (in press).
7. Available at: https://en.wikipedia.org/wiki/Proof_of_concept. Accessed January 18. 2018.
8. Harrison RK. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov 2016;15:817-818.
9. Sheiner, LB. Learning and confirming in clinical drug development. Clin Pharmacol Ther 1997;61:275-291.
10. Cook D, Brown Gearg, Alexander R. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 2014;13:419-431.
11. Morgan P, Van Der Graf PH, Feltner DE, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discovery Today 2012;17:419-424.
12. Thomas DW, Burns J, Audette J, et al. Clinical Development Success Rates 2006-2015. A BIO Industry Analysis white paper. 2016. Available at: https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf.
13. Algarni MA, Stoessl AJ. The role of biomarkers and imaging in Parkinson's Disease. Expert Rev Neurother 2016;16:187-203.
14. Chen-Plotkin AS, Kopil C, et al. Finding useful biomarkers for Parkinson's disease. Science Transl Med 2018 (in press)
15. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-635.
16. Ba F, Martin WRW. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord 2015;21:87-94.
17. Sevigny J, Suhy J, Chiao P, et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord 2016;30:1-7.
18. Nalls MA, McLean CY, Rick J, et al. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol 2015;14(10):1002-1009.
19. Irwin DJ, Grossman M, Weintraub D. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 2017;16: 55-65.
20. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs. advanced Parkinson disease. Neurology 2014;83:406-412.
21. Rizzo G, Copetti M, Arcuti S, et al. Accuracy of clinical diagnosis of Parkinson disease. Neurology 2016;86:566-576.
22. Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016;537:50-56.
23. Coric V, Salloway S, van Dyck CH, et. al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol 2015;72:1324-1333
24. Mollenhauer B, Caspell-Garcia CK, Coffey CS. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 2017;89:1-11.
25. Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson's disease: challenges and opportunities. Mov Disord 2016;31(9):1272-1282.